Clinical trial
A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With…
NCT00389090 · Keryx / AOI Pharmaceuticals, Inc., Industry · Terminated
Key facts
| NCT number | NCT00389090 |
|---|---|
| Title | A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma |
| Official title | A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma |
| Lead sponsor | Keryx / AOI Pharmaceuticals, Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioma, Astrocytoma, Oligodendroglioma, Oligoastrocytoma |
| Intervention type | Drug |
| Interventions | Temozolomide and O6-Benzylguanine |
| Enrollment | 32 |
| Start date | Oct 1, 2006 |
| Primary completion | Jun 1, 2008 |
| Completion | Feb 1, 2009 |
| First posted | Oct 18, 2006 |
| Last update posted | Feb 9, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: